FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma

被引：49
作者：
Mitrovic, Zdravko [1 ,2 ]
Aurer, Igor [1 ,2 ]
Radman, Ivo [1 ,2 ]
Ajdukovic, Radmila [4 ]
Sertic, Jadranka [2 ,3 ]
Labar, Boris [1 ,2 ]
机构：
[1] Univ Zagreb, Div Hematol, Dept Internal Med, UHC, Zagreb, Croatia
[2] Univ Zagreb, Med Sch, Zagreb, Croatia
[3] Univ Zagreb, Ctr Funct Gen, UHC, Zagreb, Croatia
[4] Univ Hosp Dubrava, Dept Internal Med, Div Hematol, Zagreb, Croatia
来源：
HAEMATOLOGICA | 2007年 / 92卷 / 07期
关键词：
Fc gamma R; single nucleotide polymorphism; rituximab; chemotherapy; diffuse large B-cell lymphoma;
D O I：
10.3324/haematol.10327
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We investigated the association of Fc gamma RIIIa and Fc gamma RIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). Fc gamma RIIIa and Fc gamma RIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via Fc gamma RIIIa and Fc gamma RIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
引用
收藏
页码：998 / 999
页数：2
相关论文
共 15 条
[1]   Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. [J].
Boettcher, S ;
Pott, C ;
Ritgen, M ;
Hiddemann, W ;
Unterhalt, M ;
Kneba, M .
BLOOD, 2004, 104 (11) :170A-171A
[2]  
Carlotti E, 2005, BLOOD, V106, p289A
[3]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship [J].
Dall'Ozzo, S ;
Tartas, S ;
Paintaud, G ;
Cartron, G ;
Colombat, P ;
Bardos, P ;
Watier, H ;
Thibault, G .
CANCER RESEARCH, 2004, 64 (13) :4664-4669
[6]   FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia [J].
Farag, SS ;
Flinn, IW ;
Modali, R ;
Lehman, TA ;
Young, D ;
Byrd, JC .
BLOOD, 2004, 103 (04) :1472-1474
[7]   Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte [J].
Feugier, P ;
Van Hoof, A ;
Sebban, C ;
Solal-Celigny, P ;
Bouabdallah, R ;
Fermé, C ;
Christian, B ;
Lepage, E ;
Tilly, H ;
Morschhauser, F ;
Gaulard, P ;
Salles, G ;
Bosly, A ;
Gisselbrecht, C ;
Reyes, F ;
Coiffier, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4117-4126
[8]   Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention [J].
Jazirehi, AR ;
Bonavida, B .
ONCOGENE, 2005, 24 (13) :2121-2143
[9]   FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma [J].
Kim, Dong Hwan ;
Du Jung, Hee ;
Kim, Jong Gwang ;
Lee, Je-Jung ;
Yang, Deok-Hwan ;
Park, Yeon Hee ;
Do, Young Rok ;
Shin, Ho Jin ;
Kim, Min Kyoung ;
Hyun, Myung Soo ;
Sohn, Sang Kyun .
BLOOD, 2006, 108 (08) :2720-2725
[10]   Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma IIIa-48L/R/H phenotype [J].
Koene, HR ;
Kleijer, M ;
Algra, J ;
Roos, D ;
vondemBorne, AEGK ;
deHaas, M .
BLOOD, 1997, 90 (03) :1109-1114
12